Trial Profile
Efficacy of tumor necrosis factor antagonists (infliximab and adalimumab) in patients with ulcerative colitis and Crohn's disease: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Golimumab; Infliximab
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2016 New trial record
- 19 Oct 2016 Results of a cohort of patients with ulcerative colitis (538) presented at the 24th United European Gastroenterology Week
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week